Table 3 Data on clinical parameters by country.

N

1796

1605

375

312

221

220

219

171

132

106

Age, median (Q1–Q3)

66 (61–71)

65 (59–70)

65 (59–70)

65 (60–71.25)

64 (58–69)

66 (59–71)

64 (57–68)

63 (58–68.5)

69 (63.75–73)

65 (58–70.75)

PSA, median (Q1–Q3)

6.66 (4.9–8.7)

6.69 (5.1–9.3)

6.4 (4.7–9.1)

6.68 (4.8–10.01)

5.93 (4.3–8.87)

5.87 (4.45–8.2)

6 (4.41–8.95)

7.67 (5.76–10.65)

6.73 (4.5–9.45)

6.75 (4.9–8.91)

PV, median (Q1–Q3)^a

51 (40–70)

51 (40–71)

60 (44.96–77.25)

47 (35–68.6)

50 (35–68.25)

44.5 (34–63.5)

45 (33–60.5)

49 (36.25–65)

50 (40–70)

53 (40–65)

DRE abnormal (%)

11.86

13.96

26.4

36.86

31.67

15

32.42

11.7

19.7

45.28

PSA density median (Q1–Q3)^a

0.12 (0.09–0.18)

0.13 (0.1–0.2)

0.11 (0.07–0.16)

0.14 (0.09–0.22)

0.12 (0.08–0.19)

0.13 (0.09–0.18)

0.13 (0.08–0.21)

0.16 (0.11–0.22)

0.14 (0.09–0.22)

0.12 (0.09–0.18)

Cases PSA < 3 (%)

5.12

2.43

10.4

8.65

8.14

6.36

12.79

2.92

9.85

5.66

Cases PSA 3–5 (%)

22.16

21.06

21.33

19.23

26.7

29.09

20.09

15.2

19.7

19.81

Cases PSA 5–10 (%)

58.57

56.2

50.13

47.12

48.42

50.91

49.32

53.22

48.48

56.6

Cases PSA 10–15 (%)

8.41

13.02

11.2

14.74

10.41

10.91

12.33

16.96

14.39

8.49

Cases PSA > 15 (%)

5.73

7.29

6.93

10.26

6.33

2.73

5.48

11.7

7.58

9.43

RNA score

38 (21–74.78)

37 (20–69)

35 (18.5–70.06)

39.46 (22–81.25)

47 (20–94)

34 (18–71)

33.04 (19.99–68.41)

33.97 (19–65.5)

43 (24–79.56)

27 (14.01–68.75)

SelectMDx result: positive, N (%); negative, N (%);

1 070 (59.58); 726 (40.42)

929 (57.88); 676 (42.12)

199 (53.07); 176 (46.93)

212 (67.95); 100 (32.05)

137 (61.99); 84 (38.01)

126 (57.27); 94 (42.73)

125 (57.08); 94 (42.92)

101 (59.06); 70 (40.94)

92 (69.7); 40 (30.3)

66 (62.26); 40 (37.74)